Showing papers by "Douglas J. Reding published in 2023"

TL;DR: In this article , the authors compared first-line treatment of advanced/metastatic non-small cell lung cancers (a/mNSCLC) with pembrolizumab monotherapy (monotherapy) versus pembrinet plus platinum-based chemotherapy combinations (combination) using multivariable Cox proportional hazards models and found that monotherapy was associated with reduced mortality and longer time to next treatment.